friday semaglutide briefing: Are appetite-suppressing drugs really a fast track to weight loss? | World news Fridays | GLP-1 Telehealth |

In February 2025, Hims acquired TrybeLabs, a home laboratory with access to an extensive database and biomarkers

Meal #24: Turkey Chili Bowl Ingredients: 1.5 cups turkey chili (made with ground turkey, beans, tomatoes) 2 tablespoons Greek yogurt as topping 1 tablespoon shredded cheese Diced onions Why it works: High protein from both turkey and beans

Said Novo Nordisk's Schneider, "As with any medication, people should consult their health care provider before making any changes to their treatment plan or for medical advice about side effects."

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) demonstrate glucose-lowering, weight-reducing, and favourable anti-inflammatory and metabolic effects.1 These emerging drug classes have been proven to reduce cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease.2 In this context, current guidelines recommend GLP-1RAs as first-line antidiabetic therapies in patients with established cardiovascular disease or high/very high cardiovascular risk.3 Semaglutide is a potent GLP-1RA used in the treatment of T2DM, with demonstrated cardiovascular benefits

(Link in Comments) To view or add a comment, sign in 328 followers

Brent James, M.D., an expert on clinical quality improvement and patient safety, told Fierce Healthcare in an email that medicine has a long history of overreacting to a new drug and then quietly moving on when the full set of circumstances become known